 Open-label, single arm study that will enroll antiretroviral-treated HIV-infected adults who are doing well post-liver or post-kidney transplant who are eligible and willing to add everolimus to their immunosuppressive regimen with a target trough level between 3-8 ngml. Calcineurin inhibitors will be decreased to obtain a 50 reduction in trough levels with the addition of everolimus. Subjects will be maintained on that regimen for 6 months. 